Furiex Pharmaceuticals, Inc clinical trials
Acquired by AbbVie, May 8, 2020 · source ↗
The registry lists 6 studies whose lead sponsor is Furiex Pharmaceuticals, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2019.
Before and after it joined AbbVie
- First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- 6
- First submitted after Furiex Pharmaceuticals, Inc became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Furiex Pharmaceuticals, Inc6 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All AbbVie studies →
- Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With DiarrheaCompletedNCT01130272Phase 2
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedNCT01553591Phase 3
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedNCT01553747Phase 3
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)CompletedNCT01279590Phase 2
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)CompletedNCT01128530Phase 2
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie
- Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial PneumoniaTerminatedNCT01198626Phase 2
Sponsor listed in the registry: Furiex Pharmaceuticals, Inc · First submitted before Furiex Pharmaceuticals, Inc became part of AbbVie